CASRAI Dictionary

Author: MCP Service

  • Research Misconduct Investigations: How ORI and UKRIO Procedures Compare

    Grant administrators rarely encounter research misconduct allegations often — but when one arrives, the clock starts immediately, and the procedural path depends entirely on which side of the Atlantic the funding sits. A US Public Health Service (PHS) grant triggers a federally regulated process overseen by the Office of Research Integrity (ORI); a UK Research England or UKRI grant triggers an institution-led process shaped, but not enforced, by the UK Research Integrity Office (UKRIO). Confusing the two — assuming ORI’s binding timelines apply to a UK case, or that UKRIO can compel an outcome the way ORI can — is a common and costly error for administrators managing cross-border collaborations.

    This guide sets out, side by side, what each body actually is, how each defines misconduct, and how the investigation stages differ — so administrators handling an allegation tied to a grant know which rulebook applies.

    How ORI and UKRIO define research misconduct

    Both frameworks agree on a common core — fabrication, falsification, and plagiarism (FFP) — but they diverge sharply in scope.

    ORI operates under 42 CFR Part 93, the PHS Policies on Research Misconduct. Its definition is deliberately narrow: research misconduct means fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results. A finding requires three elements to be met: a significant departure from accepted practices in the relevant research community; committed intentionally, knowingly, or recklessly; and proven by a preponderance of the evidence. Honest error and legitimate differences of scientific opinion are explicitly excluded.

    UKRIO, by contrast, works from a broader, non-statutory definition: “behaviours that deliberately or recklessly fall short of the standards expected in the conduct of research.” Its guidance, aligned with the UK Concordat to Support Research Integrity (Universities UK, 2019), extends beyond FFP to cover breaches of ethical approval, undeclared conflicts of interest, and mismanagement of research data — while also naming a distinct, lower-severity category, “questionable research practices” (QRPs), for avoidable errors that fall short of intentional misconduct.

    Regulator versus adviser: two different roles

    The most consequential difference is not definitional but structural: ORI is a federal oversight body; UKRIO is an independent charity with no regulatory power.

    • ORI sits within the US Department of Health and Human Services and directly oversees how institutions handle misconduct allegations tied to PHS-funded research (including NIH grants). It can conduct its own oversight review of an institution’s findings, recommend administrative actions, and refer findings to the HHS Departmental Appeals Board.
    • UKRIO was established as an independent advisory charity in 2006. It publishes a model investigation procedure that UK research organisations may adopt or adapt, offers case-by-case advice, and promotes good practice — but it does not investigate cases itself, does not mandate a single national procedure, and has no statutory sanctioning power.

    UK funders address this gap contractually rather than through a regulator. UKRI’s Guidance for Research Organisations on the Investigation of Research Misconduct (April 2025) requires any organisation receiving UKRI funding to investigate allegations against staff or students under its own Grant Terms and Conditions, with UKRI able to take funding action if an organisation fails to do so.

    How an investigation actually runs, stage by stage

    Both systems separate a preliminary triage stage from a full inquiry, but they name and time these stages differently.

    Stage ORI (US, PHS-funded research) UKRIO model (UK institutions)
    Trigger Allegation received by institution’s Research Integrity Officer Concern raised with a “Named Person” or responsible officer
    Triage Assessment: does the allegation meet the FFP definition and involve PHS funding? Initial assessment: does it fall within the misconduct procedure’s scope?
    Formal fact-finding Inquiry (institution-level, time-limited) Initial investigation to establish if there is a case to answer
    Full review Investigation, following a sufficient inquiry finding Full investigation by an academic panel, including external members
    Standard of proof Preponderance of the evidence Not codified nationally; set by each institution’s procedure
    External oversight ORI oversight review of institutional findings; report to PHS agency None mandatory; UKRIO offers advice only
    Appeal route HHS Departmental Appeals Board Institutional appeal, managed by someone other than the original Named Person

    Under the UKRIO model, once a panel reports its findings, the Named Person decides on next steps: referral to institutional disciplinary proceedings, correction of the published record, and notifying relevant funders. Where allegations are not upheld, the same procedure is meant to protect the reputation of the person accused — a feature both systems share in principle, though neither publishes comparable statistics on false-allegation rates.

    Answer-first: common questions on research misconduct

    What are the three types of research misconduct?

    Both ORI and most UK institutional policies converge on the same core triad: fabrication (inventing data or results), falsification (manipulating research materials, equipment, or data to misrepresent results), and plagiarism (using another person’s ideas, processes, or words without credit). This is often abbreviated FFP.

    What are some examples of research misconduct?

    Common examples include inventing patient consent records, selectively deleting inconvenient data points, copying text or images from another paper without attribution, and misrepresenting the outcome of a statistical test. UKRIO guidance also treats proceeding without required ethical approval as a form of misconduct, even without FFP intent.

    What counts as research misconduct?

    Conduct counts as misconduct when it represents a significant, intentional or reckless departure from accepted research standards — not an honest mistake or a genuine scientific disagreement. ORI requires proof by a preponderance of the evidence; UKRIO-aligned institutions apply a similar intent-based threshold under their own procedures.

    What this means for research administrators

    For administrators managing grants that cross jurisdictions — a common scenario in NIH-funded international collaborations or Horizon Europe partnerships involving UK institutions — three practical points follow from the comparison above:

    • Know which body has enforcement power. Only ORI can conduct oversight review and refer a case to a federal appeals process; UKRIO cannot compel an institutional outcome.
    • Check the funder’s own reporting clause. UKRI’s April 2025 guidance obliges the receiving institution — not UKRIO — to investigate and report; PHS grant terms impose parallel obligations that run through ORI.
    • Do not assume a single global timeline. ORI-regulated inquiries and investigations run to defined federal timeframes; UKRIO-aligned UK procedures are set institution by institution, so the applicable deadline sits in the local Code of Practice for Research, not in UKRIO’s own documents.

    Administrators supporting research administration functions across both systems should hold copies of both the relevant institutional misconduct procedure and the specific grant terms — the procedural detail, not the high-level definition, is where jurisdictional mismatches cause delay.

    Where the two systems are heading

    Both frameworks are converging on the same underlying principle even as their governance models remain distinct: misconduct findings should correct the scholarly record, not just discipline an individual. UKRI’s 2025 guidance tightened institutional reporting obligations, and ORI continues to publish case summaries and administrative actions as a transparency mechanism. Neither change closes the structural gap — one system regulates, the other advises — so for the foreseeable future, administrators handling cross-border allegations will need to work both playbooks rather than assume one substitutes for the other.

    As with contributor-role standards, where CASRAI originated the CRediT taxonomy in 2014 and the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, research integrity governance illustrates a broader pattern in research administration: originating bodies and enforcement bodies are frequently separate, and knowing which is which is a prerequisite for compliant practice.

  • UKRI Funding Pause 2026: An Administrator’s Planning Calendar

    The UKRI funding pause that unsettled applicant-led research funding in early 2026 is now, council by council, being lifted. UK Research and Innovation suspended several open competitions across the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC) while it re-engineered its application infrastructure, and separately paused a set of Engineering and Physical Sciences Research Council (EPSRC) programme grant areas as part of a wider budget reshape. For research offices, the practical question is no longer “what happened” but “when do I need my next round of applications ready” — and that requires a working calendar, not just a news alert.

    What is the UKRI funding pause?

    UKRI announced in January and February 2026 that it was pausing applications to several MRC and BBSRC applicant-led schemes while it moved those councils to an “always open” submission model. The stated rationale, published on UKRI’s own Pauses to funding opportunities page, is that fixed external deadlines create sharp peaks in application volume and reviewer demand; removing them is meant to smooth both.

    The pause sits inside a much larger restructuring. In late 2025, the Department for Science, Innovation and Technology (DSIT) and UKRI set out how £38.6 billion of public R&D funding over four years will be allocated across three new “buckets”: curiosity-driven research, strategic government and societal priorities, and support for innovative companies — each intended to represent roughly 50%, 25% and 25% of spend respectively, according to UKRI chief executive Professor Sir Ian Chapman. Overall UKRI funding is set to rise toward £10 billion a year by 2030, even as individual scheme timelines shift.

    A separate, unrelated cost pressure hit the Science and Technology Facilities Council (STFC), which must deliver £162 million in cost reductions by 2029–30 because of inflation and unfavourable currency exchange rates on international facility costs — prompting project leaders to model reductions of 20%, 40% and 60% to grant lines. UKRI has stated this is a cost-management issue, not a change to the funding model that paused MRC and BBSRC calls.

    Reopening timeline: council by council

    As of UKRI’s most recent update (15 June 2026), most paused schemes have already reopened. The table below consolidates confirmed dates for planning purposes; always cross-check the live UKRI Funding Finder before committing internal deadlines, since UKRI funding service records supersede any secondary summary.

    Council Scheme Status
    MRC Applicant-led research grants Reopened 7 April 2026
    MRC New investigator research grants Reopened 7 April 2026
    MRC Partnership grants Reopened 7 April 2026
    MRC Experimental medicine opportunities Reopened 30 April 2026
    MRC Proof of Concept (formerly Developmental Pathway Funding Scheme) Reopening July 2026
    MRC Impact Acceleration Awards (formerly the Gap Fund) Reopening July 2026
    MRC Fellowships, studentships, Centres of Research Excellence Never paused
    BBSRC New investigator award (applicant-led mode) Reopened
    BBSRC Standard research grant (applicant-led mode) Reopened
    EPSRC Programme grants — energy/decarbonisation, manufacturing/circular economy, quantum technologies Paused at least 12 months from December 2025; no reopening date confirmed

    All other UKRI funding opportunities — across STFC, NERC, ESRC, AHRC, Innovate UK and Research England — continued without interruption throughout the pause. UKRI has consistently described the MRC/BBSRC pauses as short and administrative rather than budgetary.

    Building a submission calendar around funder pauses

    Because the “always open” model removes fixed external deadlines from some schemes while other councils retain calls with hard cut-offs, research offices increasingly need internal, rolling calendars rather than a single annual grants diary. A practical build process:

    • Audit exposure quarterly. List every live application in the pipeline against the specific UKRI funding opportunity ID, not just the council name — pauses have applied to named schemes, not entire councils.
    • Track the Funding Finder, not secondary news. UKRI funding opportunities pages are updated directly when a scheme reopens; sector commentary (LinkedIn, Reddit, trade press) often lags by days or weeks.
    • Buffer internal deadlines. Build a two- to four-week internal review buffer ahead of any reopened scheme’s first post-pause round, since demand typically spikes when a paused call reopens.
    • Flag early-career risk separately. Vitae and Times Higher Education have both warned that even short pauses disproportionately affect early- and mid-career researchers on fixed-term contracts; research offices should track affected individuals, not just projects.
    • Distinguish administrative pauses from budget cuts. The MRC/BBSRC “always open” pause and the STFC cost-reduction exercise are separate processes with different planning implications — do not conflate a scheme reopening with a budget line being restored.

    Answer-first Q&A

    What is the UKRI funding pause?

    The UKRI funding pause refers to UKRI’s temporary suspension of several applicant-led funding opportunities within the MRC and BBSRC in early 2026, while those councils moved to an “always open” application system. It affected named schemes only, not entire council budgets, and most paused calls have since reopened.

    When will paused UKRI funding calls reopen?

    Most MRC applicant-led, new investigator and partnership grants reopened on 7 April 2026, with experimental medicine opportunities following on 30 April 2026. MRC Proof of Concept and Impact Acceleration Awards are scheduled for July 2026. BBSRC’s new investigator and standard research grants have also reopened.

    Which UKRI councils were affected by the funding pause?

    The pause primarily affected the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). Separately, EPSRC paused specific programme grant areas — energy, manufacturing and quantum technologies — for at least 12 months from December 2025. Other councils continued normally.

    How do I check current UKRI funding opportunities?

    Use the official UKRI Funding Finder at ukri.org/opportunity/, which lists every open, upcoming and recently reopened UKRI funding call directly from the UKRI funding service. This is the authoritative source; treat funder pause news coverage as a prompt to check the Finder, not a substitute for it.

    Implications for research offices

    The 2026 episode is a useful stress test of institutional grants administration. Offices that tracked pauses at the individual scheme level, rather than assuming an entire council was closed, were able to keep pipeline applicants moving toward the schemes that stayed open throughout — STFC calls, NERC, ESRC, AHRC and Innovate UK activity were unaffected by the MRC/BBSRC pause. Conversely, offices that paused all outreach on “UKRI funding” as a category lost weeks of preparation time on schemes that never stopped.

    The Campaign for Science and Engineering (CaSE) has separately pressed UKRI for clearer, comparable data on how the new three-bucket allocation model maps to historic research council spending, noting that the shift to “curiosity-driven”, “strategic priorities” and “innovative companies” buckets makes year-on-year comparison difficult. Research administrators building multi-year forecasts should treat pre-2026 allocation figures and post-restructure figures as not directly comparable, per UKRI’s own guidance to the House of Commons Science, Innovation and Technology Committee.

    Outlook for the rest of 2026

    Two threads remain open. First, EPSRC’s paused programme grant areas (energy and decarbonisation, manufacturing and the circular economy, quantum technologies) have no confirmed reopening date and are paused for a minimum of 12 months from December 2025 — institutions with pipeline work in these areas should plan for early 2027 at the earliest. Second, STFC’s £162 million cost-reduction programme runs through 2029–30 and will continue to affect grant, facility and international-collaboration budgets even as the MRC/BBSRC application pause itself is resolved. Research offices should keep these two processes on separate tracks in their planning calendars: one is an application-system change that is largely complete, the other is a multi-year budget exercise still working through its consequences.

    For institutions building longer-range research administration calendars, the practical takeaway from the 2026 pause is procedural: track named schemes via the Funding Finder rather than council-wide status, separate administrative pauses from budget decisions, and maintain a rolling internal deadline buffer for any “always open” scheme rather than relying on a fixed annual cycle.

  • UKRI Policy Fellowships 2026: Embedding Researchers in Government

    What are the UKRI Policy Fellowships 2026

    UK Research and Innovation opened its 2026 call on 9 June 2026, and the UKRI Policy Fellowships 2026 now offer 50 embedded fellowship positions across 26 host partners spanning UK government departments, devolved administrations, arm’s-length bodies and the What Works Network. Each fellowship runs for 18 months and places a researcher directly inside a policy team, working alongside civil servants on live evidence needs rather than producing research at arm’s length.

    The scheme sits within UKRI’s wider fellowship investment framework, which funds researcher mobility between academia and non-academic settings. Unlike a conventional secondment negotiated bilaterally between a university and a government department, the policy fellowships route is a competitive, centrally administered funding call with fixed strands, published cost ceilings and a standard exemplar agreement — details that matter as much to research offices as to the applicants themselves.

    Applications close at 16:00 on Thursday 10 September 2026, submitted through the UKRI Funding Service by the applicant’s employing research organisation.

    Funding strands, amounts and cost-sharing

    The 2026 call is organised into three funding strands, each with its own focus, eligible career stage and full economic cost (FEC) ceiling. UKRI funds 80% of the FEC; the remaining 20% is met by the fellow’s employing research organisation, consistent with the standard UKRI research grant cost-sharing model rather than a fully funded secondment.

    Strand Focus FEC ceiling Career stage
    Core Policy Fellowships Priority areas across UK and devolved government Up to £180,000 Early or mid-career
    What Works Innovation Fellowships Homelessness, policing and place, via the What Works Network Up to £220,000 All career stages
    Natural Hazards and Resilience Fellowships System resilience and preparedness for environmental risk Up to £280,000 Early or mid-career

    Host partners named against these strands include the Department for Business and Trade, the Ministry of Housing, Communities and Local Government, the Scottish Government, the Department of Health and Social Care, the UK Health Security Agency, the Ministry of Justice, the Home Office, the Department for Education, the Cabinet Office, the Environment Agency, the Centre for Homelessness Impact and the Wales Centre for Public Policy, among others. Thematic clusters span economic growth and industrial strategy, health inequalities, justice and public safety, education, housing and place, and the use of data and AI in government.

    Eligibility, key dates and how to apply

    Applicants must hold a doctorate or equivalent research experience, be based at a UKRI-eligible research organisation, and demonstrate subject-matter expertise relevant to a specific fellowship position. UKRI is explicit that career stage is not time-bound by years since doctorate; a researcher without a PhD may still qualify if they can evidence an equivalent sustained research-focused role. Researchers who have already undertaken or are currently undertaking a UKRI policy fellowship are not eligible to reapply.

    • Call opened: 9 June 2026, 09:00
    • Applicant webinar: 25 June 2026
    • Deadline: 10 September 2026, 16:00
    • Shortlisting: October to November 2026
    • Interviews: January 2027
    • Decisions: February 2027
    • Fellowship start: 1 May 2027

    Only the lead research organisation can submit an application to UKRI, though the fellowship agreement itself is negotiated between three parties: the host partner, the fellow, and the employing research organisation. Fellows must also pass any security, nationality and clearance checks the specific host requires before the placement can begin.

    What is the deadline for UKRI Policy Fellowships 2026?

    Applications for the UKRI Policy Fellowships 2026 close at 16:00 on Thursday 10 September 2026, submitted via the UKRI Funding Service. Only the applicant’s lead employing research organisation can make the submission, so institutional sign-off must be secured well before this deadline.

    Who is eligible to apply for UKRI policy fellowships?

    Eligible applicants hold a doctorate or equivalent research experience, are based at a UKRI-eligible research organisation, and meet the early or mid-career descriptor for Core Policy and Natural Hazards strands. What Works Innovation Fellowships are open to researchers at all career stages, including those without a completed doctorate.

    How many UKRI policy fellowship positions are available in 2026?

    UKRI is funding 50 fellowship positions across 26 host partners in the 2026 call, spanning UK government departments, devolved administrations, arm’s-length bodies and What Works Network members. Positions are distributed unevenly across the three funding strands and named host organisations.

    How is UKRI policy fellowship funding structured?

    UKRI funds 80% of the full economic cost of each fellowship, up to strand-specific ceilings of £180,000, £220,000 or £280,000. The employing research organisation covers the remaining 20%, matching UKRI’s standard grant cost-sharing model rather than a fully externally funded secondment.

    How research offices administer secondment agreements and reporting

    For research administrators, the operational detail sits below the headline figures. UKRI requires a formal fellowship or secondment agreement between the host partner, the fellow and the employing research organisation before a placement starts. UKRI has published an exemplar agreement, developed in consultation with UKRI Legal, central government departments and the university sector, and advises institutions to review it well ahead of submission rather than treating it as a post-award formality.

    This has direct implications for how institutions resource the administration of placement schemes:

    • Costing and 20% co-funding sign-off: Because UKRI funds only 80% of FEC, finance teams must confirm the department or faculty can cover the balance before the application is submitted, not after the award is made.
    • Compliance checks: UKRI states plainly that research office and finance teams undertake checks on hosting arrangements and financial eligibility, while ultimate responsibility for compliance remains with the applicant — a split of accountability research offices should document in their own sign-off workflow.
    • Host-specific clearance: Security and nationality checks vary by host department, so administrators cannot rely on a single institutional template; each placement’s clearance requirements need checking against the specific host’s published criteria.
    • Mentor and team roles: Early-career applicants must name a senior mentor from their employing organisation, adding a role that research offices need to track alongside the fellow and the host contact.
    • Reporting during placement: Fellows remain employed by their home institution throughout, so payroll, HR and reporting lines stay with the research organisation even while day-to-day line management sits with the host — a dual-reporting structure that research administration systems must be configured to reflect.

    This three-way agreement structure — host, fellow, employer — is the genuine administrative distinction of the UKRI scheme compared with informally negotiated academic-government exchanges, and it is the detail most coverage of the 2026 call omits in favour of headline position and funding counts.

    Implications for institutions and applicants

    Research offices supporting an applicant should treat the fellowship agreement review as a parallel workstream to the academic proposal, not a downstream task. Given the FEC ceilings scale with strand rather than individual placement complexity, institutions should also confirm early whether their standard overhead recovery models accommodate an 80/20 split embedded within a government host, rather than a conventional university-based grant.

    Applicants working with sensitive or linked administrative datasets should note that feasibility assessments — including secure data access approvals — need to be scoped against the 18-month fellowship window from the outset, since data access timelines can otherwise outrun the placement itself.

    Outlook: what happens after the September deadline

    With shortlisting running October to November 2026, interviews in January 2027 and a fellowship start date of 1 May 2027, institutions have a multi-month gap between submission and confirmed placement — a window research offices can use to finalise co-funding approvals, mentor arrangements and host-specific clearance paperwork rather than leaving them until decisions land. As UKRI continues to expand policy fellowship strands beyond their original remit, research administrators are likely to see this three-party agreement model applied to further embedded-researcher schemes, making early familiarity with the exemplar agreement a transferable skill rather than a one-off task.

  • NIH Grant Terminations in 2026: What Was Cancelled, What Was Restored, and Why

    What happened: the 2025-2026 NIH termination wave

    Beginning in March 2025, the National Institutes of Health cancelled thousands of active research awards in one of the largest disruptions to federal biomedical funding in decades. A peer-reviewed analysis published in the Proceedings of the National Academy of Sciences in 2026 counted 2,291 active NIH research grants terminated in the initial wave, withdrawing an estimated $2.45 billion in committed funding. NIH grant terminations continued through the spring, and by late May 2025 Harvard T.H. Chan School of Public Health researchers tracking the cuts put the cumulative total at roughly 2,100 grants worth approximately $9.5 billion.

    Independent counts diverged because institutions and awarding offices reported figures at different points in a fast-moving process. The Association of American Medical Colleges recorded 777 terminated grants representing $1.9 billion as of 5 May 2025, while an implementation-science analysis published in PubMed Central counted 702 terminations as of 5 April 2025. The variance reflects the pace of the cuts rather than disagreement about their occurrence.

    Which grants and research topics were targeted

    Termination notices sent to grantees cited a shift in agency funding priorities away from topics the administration characterised as “unscientific” or as promoting discrimination. Research areas disproportionately affected included:

    • LGBT+ health and gender-identity research
    • Diversity, equity, and inclusion (DEI) initiatives in the biomedical workforce
    • Vaccine hesitancy and confidence studies
    • Health equity and racial health-disparities research
    • Climate change and environmental-health research

    Reporting by Applied Clinical Trials Online found that 20% of terminated grants were early-career training awards, a category central to sustaining the biomedical research pipeline. A subsequent analysis found the cuts fell disproportionately on Black, Indigenous, and other minority researchers, as well as investigators from sexual and gender-minority communities — a pattern that later became central to the legal challenges against the terminations.

    Court-ordered restorations: the timeline

    Multiple lawsuits challenged the terminations as procedurally unlawful and discriminatory. The table below summarises the major rulings tracked through mid-2026.

    Date Ruling / event Outcome
    16 June 2025 Judge William Young (D. Mass.), APHA v. NIH Ordered NIH to restore 367 grants worth nearly $3.8 billion; found the termination process “arbitrary and capricious” and discriminatory toward LGBTQ-related research
    25 June 2025 NIH response to court order NIH ceased issuing new terminations of “politically sensitive” grants while the ruling was contested
    August 2025 Federal court order, UCLA class action Ordered restoration of NSF grants suspended at UCLA from 1 August 2025
    September 2025 Federal court order, UCLA Ordered restoration of NIH funding suspended at UCLA from 31 July 2025; NIH reinstated the awards
    May 2026 Ninth Circuit Court of Appeals Upheld reinstatement of grants terminated under DEI- and environmental-justice-related executive orders, the first major appellate ruling on the issue

    The Department of Health and Human Services has pursued appeals against several of these rulings, so the restoration list is not static. Institutions should treat any given month’s figures as a snapshot rather than a final count.

    Answer-first: common questions about NIH grant terminations

    How many NIH grants have been terminated?

    Counts vary by source and date because the terminations rolled out over several months. Published figures range from 702 grants in early April 2025 to 2,291 grants worth $2.45 billion in the fullest peer-reviewed accounting, published in PNAS in 2026.

    Have any terminated NIH grants been restored?

    Yes. A federal judge ordered 367 grants restored in June 2025 following the APHA v. NIH ruling, and separate court orders restored NIH and NSF funding to UCLA researchers later that year. In May 2026 the Ninth Circuit Court of Appeals upheld further reinstatements.

    How can a research office check if a specific NIH grant was terminated?

    Research offices should cross-check award numbers against NIH RePORTER, the HHS TAGGS terminated-grants list, and USASpending.gov, then corroborate against the crowdsourced Grant Watch database, which aggregates termination notices submitted directly by affected principal investigators.

    What is the Grant Watch database?

    Grant Watch is an independent tracker built by Harvard T.H. Chan School of Public Health researcher Scott Delaney and computational researcher Noam Ross, combining government data with crowdsourced submissions to document NIH and NSF grant terminations that agency reporting has not consistently disclosed.

    Monitoring exposure: RePORTER, TAGGS, and tracker databases

    For sponsored-programmes offices, the operational question is not just what happened nationally but which of an institution’s own awards are exposed. No single federal system currently gives a real-time, authoritative picture of terminations and restorations together, so offices need to triangulate across sources.

    Tool Custodian Best for
    NIH RePORTER National Institutes of Health Authoritative award status, PI, institution, and funding history lookups
    HHS TAGGS (terminated-grants list) U.S. Department of Health and Human Services Official, periodically updated PDF/CSV of terminated HHS awards by agency
    USASpending.gov U.S. Treasury / OMB Government-wide obligation and de-obligation records across all federal awards
    Grant Watch Independent researcher-run project Early, crowdsourced signal on terminations before official lists update

    A practical monitoring routine for a research office includes:

    1. Reconcile the institution’s active award list against NIH RePORTER monthly, flagging any status changes.
    2. Cross-check flagged awards against the HHS TAGGS terminated-grants file for confirmation of formal termination.
    3. Monitor Grant Watch and institutional legal counsel updates for early warning and litigation status, since court-ordered restorations can lag or precede official RePORTER updates.
    4. Maintain a standing register of affected PIs so restoration notices — which are sometimes issued quietly — are not missed.

    Because restorations have followed litigation rather than routine agency process, research offices that rely solely on award letters risk missing reinstatements that require the institution to formally re-accept funding within a compliance window. Building this monitoring into research administration workflows, rather than treating it as a one-off compliance exercise, is now a standing requirement for institutions with federally funded portfolios.

    Implications for institutions, PIs, and research offices

    The termination-and-restoration cycle has practical consequences beyond the immediate funding gap. Institutions have had to decide whether to bridge-fund affected projects, hold staff and data-collection activities in limbo, or wind down studies that may later be reinstated. Early-career researchers, who held a disproportionate share of terminated training awards, face particular career risk from even temporary funding gaps.

    The pattern of litigation-driven reinstatement also means compliance offices cannot treat a termination notice as final without checking litigation status — a departure from how terminations were historically administered. As appellate rulings such as the May 2026 Ninth Circuit decision accumulate, research offices should expect further reinstatements to arrive on a rolling basis rather than as a single resolution, making ongoing monitoring — not a one-time audit — the operationally necessary posture through the remainder of 2026.

  • NIH Reinstates South Africa Grant Funding: Inside the Subaward Policy Reversal

    The US National Institutes of Health (NIH) has reinstated South Africa grant funding that had been frozen for months, lifting a hold on payments for scores of existing awards after a policy change nearly collapsed one of its largest overseas HIV and tuberculosis research partnerships. The reversal does not undo the underlying policy — a ban on new foreign subawards — but it restores cash flow to active clinical trials and signals how the NIH intends to manage international collaboration going forward.

    For research administrators, sponsored-programs offices, and institutional leaders outside the United States, the episode is a case study in how quickly a funder’s compliance architecture can change, and how little advance notice foreign partners typically get.

    What happened: the subaward ban and its fallout

    On 1 May 2025, the NIH announced it would no longer permit foreign “subawards” — the standard mechanism by which a US-based principal investigator holding a “prime” NIH grant channels a portion of the funds to a collaborating institution abroad. Going forward, foreign partners would instead need to apply for direct awards from the NIH itself.

    The agency framed the change as an effort to improve financial tracking and safeguard national security. In practice, the shift landed on a system that was not ready for it: the NIH’s own staff guidance warned that the infrastructure for processing direct foreign awards might not be operational until 30 September 2025.

    South Africa was disproportionately exposed. The country hosts one of the NIH’s largest overseas research footprints, particularly in HIV and TB clinical trials run through institutions such as the University of the Witwatersrand and the South African Medical Research Council (SAMRC). Disruption had begun even earlier: in March 2025, the NIH moved to freeze or terminate roughly 280 grants tied to South African projects, well before the formal subaward ban took effect.

    The scale of the exposure was significant. In the prior funding year, the NIH had supported approximately 3,600 subawards in foreign countries worth more than $400 million in total. South African institutions alone had been receiving an estimated $100–150 million a year in direct and sub-awarded NIH funding, according to analysis published by Physicians for Human Rights.

    Timeline: from termination to reinstatement

    The sequence of events matters for any institution assessing exposure to future funder policy shifts. The table below sets out the key dates drawn from contemporaneous reporting.

    Date Development
    March 2025 NIH moves to freeze or terminate roughly 280 grants for South African projects
    1 May 2025 NIH formally bans new foreign subawards; requires direct-award applications instead
    27 June 2025 NIH grants official Michelle Bulls confirms existing clinical-research subawards can continue via a new “supplement” mechanism; roughly 100 prime awards to South African researchers permitted to proceed
    30 June 2025 Staff guidance carves out an exception for human-subjects research submitted before the ban
    July 2025 NIH lifts the payment hold on scores of existing South Africa grants, without public explanation
    30 September 2025 (target) NIH’s new direct-award tracking system for foreign partners due to be operational

    Notably, the reinstatement applied to grants that had been frozen, not to the larger population of grants that had been fully terminated. Separately, the NIH has also been under court order to reinstate a portion of the more than 2,000 grants it cancelled nationwide over politically sensitive research topics — a distinct, US-domestic dispute that runs in parallel to the foreign-subaward story.

    Key questions answered

    Have NIH grants been reinstated?

    Yes, partially. In July 2025 the NIH lifted a payment hold on scores of existing South Africa grants and introduced a “supplement” mechanism letting foreign clinical-research subawards continue. It remains unclear whether grants that were fully terminated, rather than merely frozen, will also be restored.

    How many NIH grants have been canceled?

    Across all research areas, the federal government terminated approximately 2,100 NIH grants worth around $9.5 billion, according to tracking by Harvard T.H. Chan School of Public Health. Within that total, roughly 280 South Africa-linked grants were separately frozen or ended starting in March 2025.

    Do South African universities face a funding crisis from the freeze?

    Yes. Institutions including the University of Cape Town and Wits University reported severe financial strain, staff layoffs, and applications for emergency government funding — with the Wits Health Consortium reportedly seeking over R1.8 billion from South Africa’s Treasury to offset the shortfall.

    What it means for foreign subawardees and research offices

    The reversal is narrow, temporary, and administratively burdensome — not a return to the pre-2025 status quo. Institutions that rely on NIH funding through US-based collaborators should treat the following as durable changes rather than transient disruption:

    • Subawards are being phased out for new and renewal applications. The direct-award model is now the NIH’s default path for foreign partners, and institutions should build direct-application capacity rather than assuming subaward continuity.
    • The supplement mechanism is a stopgap, not a policy. An NIH grants official described the conversion process as “a huge administrative lift” — sponsored-programs offices should expect delays and duplicated paperwork during the transition period.
    • Frozen and terminated are legally distinct categories. Institutions holding terminated (not just frozen) awards should not assume the July reinstatement applies to them without written confirmation from their program officer.
    • Compliance offices need contingency plans. Bodies such as NCURA, EARMA, and ARMA have flagged funder-driven subaward volatility as a growing risk category for institutional research administration — not unique to the NIH or to South Africa.

    For research administration teams managing sponsored programmes with US federal funders, the practical lesson is procedural: subaward agreements should now include explicit clauses addressing funder-initiated conversion to direct awards, and institutions should maintain the internal capacity to submit direct NIH applications on short notice.

    What to track going forward

    Three open questions will determine whether this remains a contained South Africa story or a template applied more broadly to NIH’s international grant portfolio.

    First, whether the 30 September 2025 target for a functioning direct-award tracking system holds, or whether the interim supplement mechanism becomes a permanent parallel process. Second, whether the reinstatement logic extends to grants that were fully terminated rather than frozen — a distinction the NIH has not yet resolved publicly. Third, whether other major NIH partner countries in HIV, TB, and global-health research face the same subaward-to-direct-award transition South Africa has already been through.

    For institutions with NIH-funded international partnerships, the prudent posture is to document funder communications carefully, confirm award status (frozen versus terminated) in writing, and monitor NIH policy notices for extensions or modifications to the direct-award transition timeline.

  • Cooperative Agreement vs Grant: What the Law Actually Requires

    Every research administrator eventually meets an award letter that does not say “grant” at the top. Understanding a cooperative agreement vs grant distinction is not academic housekeeping — it determines who signs off on your data collection plan, how often you report, and whether a federal programme officer can direct the day-to-day conduct of your funded work. The dividing line was set in US law nearly fifty years ago, and it still governs every award letter issued by NSF, NIH, DOE, USDA and dozens of other federal agencies.

    The Federal Grant and Cooperative Agreement Act of 1977 (Public Law 95-224, codified at 31 U.S.C. §§6301–6308) requires every executive agency to classify a funding relationship as one of three legal instruments before it awards money: a procurement contract, a grant agreement, or a cooperative agreement.

    The statute draws the line on two questions, applied in sequence:

    • Is the government acquiring something for its own direct benefit? If yes, the instrument must be a procurement contract under 31 U.S.C. §6303, governed by the Federal Acquisition Regulation (FAR).
    • If the purpose is instead to support or stimulate a public activity, is “substantial involvement” expected between the agency and the recipient? If no, it is a grant agreement (31 U.S.C. §6304). If yes, it is a cooperative agreement (31 U.S.C. §6305).

    Both grants and cooperative agreements are forms of federal financial assistance and sit under the Office of Management and Budget’s Uniform Guidance at 2 CFR Part 200, not the FAR. That single fact explains why grants and cooperative agreements share so much administrative machinery — standard forms, cost principles, audit requirements — while contracts follow an entirely separate acquisition regime.

    Grant vs cooperative agreement vs contract: the three-way test

    The clearest way to see the distinction is side by side. The table below reflects the statutory test as applied consistently across federal science agencies, including the framework published by the US Department of Energy’s Office of Science.

    Feature Grant Cooperative agreement Procurement contract
    Statutory basis 31 U.S.C. §6304 31 U.S.C. §6305 31 U.S.C. §6303
    Purpose Support/stimulate a public activity Support/stimulate a public activity Acquire goods/services for the government
    Federal involvement Oversight and stewardship only “Substantial involvement” expected Direction and control of delivery
    Governing rules 2 CFR Part 200 (Uniform Guidance) 2 CFR Part 200 (Uniform Guidance) Federal Acquisition Regulation
    Who owns the IP Recipient, typically Recipient, typically May transfer to government
    Scope of work Defined by applicant/PI Negotiated jointly Defined by the sponsoring agency

    A cooperative agreement therefore sits between a grant and a contract without being either. It is a financial assistance award — like a grant — but the awarding agency retains an active, defined role in carrying out the funded activity, which is the hallmark of a contract relationship without the acquisition purpose that would make it one.

    Answer-first: common questions on cooperative agreements

    What is a cooperative agreement?

    A cooperative agreement is a legal instrument of federal financial assistance used when an agency expects “substantial involvement” in a project it is funding for a public purpose. Unlike a grant, the agency actively participates — reviewing milestones, coordinating sub-awards, or contributing technical direction — rather than simply monitoring progress from a distance.

    What is the difference between a grant agreement and a contract?

    A grant transfers value to support a public purpose the recipient defines and controls; a contract acquires goods or services for the government’s direct benefit under terms the government specifies. Grants follow Uniform Guidance cost principles; contracts follow FAR-based competition, protest, and deliverable-acceptance rules.

    What is the difference between a grant and a cooperative agreement?

    Both are financial assistance instruments for public-purpose activities, but a cooperative agreement requires anticipated substantial federal involvement — joint design, resource allocation across sites, or active participation in research conduct — while a grant assumes the recipient carries out the work with only routine agency oversight.

    Is a cooperative agreement legally binding?

    Yes. A federal cooperative agreement is a binding award under 31 U.S.C. §6305 with enforceable terms, reporting obligations, and audit exposure. Do not confuse it with a private-sector “cooperation agreement” between two companies — a different, non-statutory instrument that follows ordinary contract law rather than federal assistance regulation.

    Why the distinction matters for research administrators

    The choice of instrument is not cosmetic; it changes real obligations for every principal investigator and sponsored-programmes office.

    • Reporting cadence and content. Cooperative agreements typically carry more frequent, and more detailed, progress reporting than a comparable grant, because the agency needs current information to exercise its involvement rights.
    • Prior-approval requirements. Where a grant might allow a principal investigator to reallocate budget or change key personnel within defined limits without agency sign-off, a cooperative agreement more often requires the agency’s prior approval at defined decision points.
    • Programmatic authority. Under a cooperative agreement, an agency programme officer may participate in study design, site selection, or data-sharing decisions — participation that would be inappropriate, and potentially instrument-converting, under a grant.
    • Audit and subrecipient monitoring. Both instruments sit under Uniform Guidance audit requirements, but the active federal role in a cooperative agreement often means closer scrutiny of how funds move to subrecipients and consortium partners.

    NSF cooperative agreement awards illustrate the pattern well. The National Science Foundation uses cooperative agreements — rather than grants — for its large research infrastructure programmes, including major facilities where NSF staff are directly engaged in oversight of construction, operations, and multi-institution coordination. The same NSF portfolio uses ordinary grants for the vast majority of individual investigator-led research, where the Foundation’s role is genuinely limited to stewardship.

    This is also where the distinction between grant administration vs grant management becomes practically important. Grant administration — the institutional function performed by a sponsored-programmes or research-administration office — covers pre-award compliance review, negotiation of terms, and post-award financial and regulatory oversight, and it must flex significantly for a cooperative agreement’s heavier approval and reporting load. Grant management, by contrast, is the principal investigator’s day-to-day delivery of the funded work. Bodies such as NCURA, EARMA, ARMA and INORMS increasingly treat instrument classification as a first checkpoint in research administration training precisely because misclassifying an award — or failing to staff for a cooperative agreement’s collaborative obligations — creates downstream compliance risk that a standard grant checklist will not catch.

    Institutions building out their research administration compliance frameworks should treat instrument type as a triage question at intake, not an afterthought discovered mid-project when a programme officer asks to review a dataset before publication.

    Looking ahead

    The Federal Grant and Cooperative Agreement Act has not been substantively rewritten since 1977, but its “substantial involvement” test is being tested constantly by newer funding models — public-private consortia, multi-agency infrastructure awards, and international collaborations that blend federal and non-federal sponsors. As funders experiment with more collaborative funding structures, research administrators who can correctly classify an instrument at the proposal stage — and staff accordingly — will be better placed to meet reporting obligations and protect institutional standing than those who treat “grant” as a catch-all label for any federal award. Consulting authoritative terminology resources, including a controlled research administration dictionary, helps ensure proposal teams and compliance offices are using these terms consistently across an institution.

  • NIH Indirect Cost Cap Lawsuit Ends: Final Ruling Explained

    The NIH indirect cost cap lawsuit is over. In early April 2026, the deadline for the Trump administration to petition the US Supreme Court over its blocked attempt to cap National Institutes of Health facilities-and-administrative (F&A) reimbursements at 15% passed without a filing, closing out fourteen months of litigation that began with a February 2025 policy notice and ended with a unanimous First Circuit Court of Appeals ruling in January 2026. For research administrators who have spent a year budgeting around uncertainty, the case is now legally settled — though, as this article explains, the underlying policy debate is not.

    Timeline: From 15% Cap Proposal to Final Ruling

    The dispute began on 7 February 2025, when NIH issued guidance capping reimbursement of indirect costs — overheads such as facility maintenance, laboratory utilities, and administrative support — at 15% for all new and existing grants, replacing rates individually negotiated with each institution that typically ranged from 30% to 70%. Twenty-two state attorneys general, along with universities and organisations including the Association of American Medical Colleges (AAMC), challenged the notice within days.

    Date Development
    7 February 2025 NIH issues Supplemental Guidance capping indirect cost reimbursement at 15%
    10 February 2025 State attorneys general and higher-education associations file suit
    7 April 2025 US District Court issues a permanent injunction blocking the cap nationwide
    6 January 2026 First Circuit Court of Appeals unanimously upholds the injunction
    Early April 2026 90-day Supreme Court appeal deadline lapses; administration formally drops the case

    NIH’s own public estimate, cited in the appeals court’s opinion, put the fiscal effect of the 15% rate at roughly $4 billion in annual reimbursement withheld from institutions; the AAMC separately estimated the cap would have disrupted $6.5 billion in previously committed research funding had it taken effect immediately.

    Why the Appeals Court Ruled the Cap Unlawful

    The First Circuit’s 6 January 2026 decision rested on two grounds. First, the panel found that a flat cap conflicts with Department of Health and Human Services regulations requiring indirect cost rates to be individually negotiated with each institution rather than imposed uniformly. Second, and more decisively, the court pointed to an appropriations rider that Congress has re-enacted every year since 2017 explicitly preventing NIH from altering how it reimburses indirect costs outside the negotiated-rate process.

    Jurisdiction was itself contested. The administration argued that funding disputes belonged before the Court of Federal Claims rather than a district court, drawing on a Supreme Court precedent from a separate case over NIH grant terminations. Writing for the panel, Judge Kermit V. Lipez distinguished that precedent using Justice Amy Coney Barrett’s concurrence in the earlier grant-termination case, which separated challenges to agency-wide policy (properly heard in district court) from disputes over the withholding of already-awarded contract funds. The proposed rate cap, the court reasoned, was exactly this kind of general policy — so the original district court injunction stood.

    With the ruling upheld and no Supreme Court petition filed inside the 90-day statutory window, the injunction is now final and nationwide. The administration also quietly withdrew parallel appeals over comparable rate-cap policies at the Department of Energy, the National Science Foundation, and the Department of Defense, effectively closing the entire family of indirect-cost-cap litigation at once.

    Answer-First Q&A

    What did the NIH’s proposed 15% indirect cost cap actually change?

    The NIH’s February 2025 policy would have replaced individually negotiated facilities-and-administrative rates, which typically ran between 30% and 70%, with a flat 15% cap on all new and existing grants. Institutions, state attorneys general, and higher-education associations argued this ignored real infrastructure costs and breached appropriations law protecting negotiated rates.

    Why did the appeals court say the cap was unlawful?

    The First Circuit Court of Appeals found the cap violated a Department of Health and Human Services regulation requiring individually negotiated indirect cost rates, plus an appropriations rider Congress has re-enacted since 2017 that bars NIH from unilaterally changing how indirect costs are reimbursed without new legislative authority.

    Is the NIH indirect cost cap litigation completely over?

    Yes. The Trump administration’s 90-day window to petition the Supreme Court after the January 2026 First Circuit ruling expired in early April 2026 without a filing. That deadline lapse permanently ends the case, leaving the nationwide permanent injunction against the 15% cap in place.

    Does the ruling mean indirect cost policy will never change again?

    No. The courts blocked only this specific capping mechanism, not future reform. A 2025 executive order still directs federal agencies to favour lower-overhead institutions in funding decisions, and groups such as AAMC continue advancing the FAIR model as a negotiated alternative to a flat cap.

    What the Ruling Means for Institutions

    For research administrators, the practical effect is restoration of the status quo ante: negotiated F&A rates on NIH awards remain enforceable exactly as they were before February 2025. There is no retroactive cap to reconcile, and no need to budget contingency reserves against a 15% ceiling that never took legal effect. That said, the ruling changes the litigation posture, not the political one — a distinction that matters for planning:

    • Negotiated rate agreements stand. Institutions’ existing Facilities and Administrative (F&A) rate agreements with their cognizant federal agency remain the operative basis for NIH indirect cost reimbursement.
    • Subaward flow-through is unaffected. The cap would have applied to NIH indirect costs on subawards as well as prime awards; with the injunction final, subrecipient reimbursement continues on negotiated terms.
    • Executive-order pressure persists. A separate August 2025 executive order instructing agencies to weight funding decisions toward lower-overhead institutions was not addressed by this litigation and remains in force as a policy lever.
    • Watch agency-specific rulemaking. Because the appeals court’s reasoning turned on the specific appropriations rider protecting NIH, institutions should not assume identical legal protection automatically extends to every other federal funder without agency-specific statutory analysis.
    • Transparency debate continues. AAMC’s Heather Pierce has been explicit that the litigation’s end does not resolve underlying questions about how explainable indirect cost rates are to Congress and taxpayers — a conversation research offices should expect to continue independent of any court order.

    What Comes Next for Indirect Cost Policy

    The NIH indirect cost cap lawsuit’s conclusion removes a year of acute legal uncertainty from institutional budgeting, but it does not close the broader policy conversation about how NIH direct and indirect costs are structured, negotiated, or explained. Two threads are worth tracking. First, the AAMC-backed Financial Accountability in Research (FAIR) model proposes a more granular, activity-based way of tracking indirect cost expenses — an alternative to both the old negotiated-rate system and the abandoned flat cap, and one that could shape future NIH grant funding policy change through negotiation rather than unilateral notice. Second, the administration’s remaining lever — the executive order favouring lower-overhead applicants in funding decisions — operates through discretionary award selection rather than rate-setting, so it sits outside what this ruling addressed and could still influence which institutions receive awards even as reimbursement rates themselves stay protected.

    For institutions tracking research administration standards and terminology more broadly, CASRAI’s research administration resources and open glossary of research-administration terms provide grounding definitions that sit alongside funder policy developments like this one.

  • NIH Biosketch Rules in 2026: The SciENcv Common Form Compliance Guide

    What is the NIH biosketch, and why did it just change?

    The NIH biosketch is the standardised biographical document that every senior/key person and other significant contributor must submit with an NIH grant application, so that peer reviewers and programme staff can judge whether the named personnel have the expertise, track record, and capacity to carry out the proposed work.

    Since 25 January 2026, that document has changed shape. Driven by federal research-security directives (NSPM-33) that push all federal funding agencies toward shared “Common Forms,” NIH retired the familiar single Word-based biosketch template. In its place sits the Biographical Sketch Common Form, produced exclusively through SciENcv (Science Experts Network Curriculum Vitae), the NIH-hosted researcher-profile system.

    The change is not cosmetic. It affects how contributions are documented, what identifiers are mandatory, and how compliance is checked before submission.

    The new Biographical Sketch Common Form: structure and sections

    The old biosketch was a single four-part document. The new format splits the content across two linked outputs generated together in SciENcv: the Biographical Sketch Common Form itself, and a separate NIH Biographical Sketch Supplement.

    • Biographical Sketch Common Form — identifying information, a Persistent Identifier (ORCID iD) field, professional preparation, appointments and positions, and a “Products” list.
    • NIH Biographical Sketch Supplement — Personal Statement, Honors, and Contributions to Science, all cross-referenced to the Products list rather than carrying their own citations.
    • Section D (Scholastic Performance), previously required only for Fellowship applications, has been eliminated entirely.

    The table below summarises the practical differences institutions need to build into their internal checklists.

    Feature Pre-2026 biosketch New Biographical Sketch Common Form (SciENcv)
    Production method Manually formatted Word/PDF template Generated and digitally certified inside SciENcv only
    Document structure Single document, four sections Common Form plus a separate Biosketch Supplement
    Page limit Fixed 5-page limit No overall page limit; section-level character and entry limits apply
    Citations in Personal Statement Permitted Not permitted; narrative must reference numbered items in the Products list
    Products/contributions cap Up to 5 contributions, 4 publications each Up to 5 products most closely related to the project, plus up to 5 other significant products
    Scholastic Performance (Fellowships) Required (Section D) Removed
    ORCID iD Optional/recommended Mandatory, linked to eRA Commons
    Certification Signature on submission package Digital certification required in SciENcv before the locked PDF can be downloaded

    SciENcv: how to generate a compliant biosketch

    Every senior/key person needs a My NCBI account linked to SciENcv, accessed consistently through one sign-in route — eRA Commons, ORCID, or an institutional credential — since switching methods can silently spawn duplicate profiles.

    Three linked steps matter most for research offices tracking each named investigator:

    1. Obtain and verify an ORCID iD, then link it to both the eRA Commons account and the SciENcv profile — now a mandatory field, not an optional courtesy line.
    2. Populate the Common Form sections (preparation, positions, Products) and the linked Supplement (Personal Statement, Honors, Contributions to Science), keeping product references numbered consistently across both documents.
    3. Digitally certify the biosketch in SciENcv, including the attestation of non-participation in a Malign Foreign Talent Recruitment Program, before downloading the final locked PDF.

    Because SciENcv applies formatting automatically and locks the PDF after certification, manual font and margin errors — a historically common source of NIH compliance rejections — are largely engineered out. What replaces them is a new failure mode: incomplete or unlinked identifiers, which block certification outright rather than drawing a reviewer’s note.

    Page limits, character limits, and format rules

    This is the single most misunderstood change, and it is worth stating plainly because several existing summaries online still describe the old rule as current: the traditional 5-page limit no longer applies. SciENcv does not enforce a page count on the Common Form or Supplement.

    In its place, NIH built section-level constraints directly into the SciENcv fields:

    • The Products section is capped at five items most closely related to the proposed project, plus up to five other significant products regardless of relevance to the current project.
    • The Personal Statement and Contributions to Science narratives carry character limits enforced by the SciENcv text fields rather than a page count.
    • Citations may no longer be embedded directly in the Personal Statement; instead, applicants reference the numbered Products list.
    • Template integrity rules persist from the legacy format: no deleted section headings, no inserted figures or tables, and no hyperlinks other than a link to a federal repository of the applicant’s published work (for example, My Bibliography).

    Research administrators verifying compliance should stop counting pages and instead check that every named person has a current ORCID-linked SciENcv profile, the Products list stays within the five-plus-five cap, and the PDF carries a SciENcv digital certification mark rather than a typed signature block.

    Answer-first Q&A

    What is an NIH biosketch?

    An NIH biosketch is a standardised biographical document required for every senior/key person and other significant contributor named on an NIH grant application. It summarises education, appointments, and research contributions so that reviewers can assess whether the named personnel can carry out the proposed work.

    Is an NIH biosketch the same as a CV?

    No. A biosketch is similar to a CV but far more constrained: it follows a fixed government template, limits the number of listed products, and (in the current SciENcv-generated version) must be digitally certified. A full curriculum vitae has no such structural or format restrictions.

    What does the new NIH biosketch look like?

    The new biosketch is generated entirely inside SciENcv as two linked outputs: the Biographical Sketch Common Form (identifying information, positions, Products) and the NIH Biographical Sketch Supplement (Personal Statement, Honors, Contributions to Science), both requiring digital certification before download.

    What is the difference between the NIH biosketch and the NIH Biosketch Common Form?

    “NIH biosketch” is the general term for the required biographical document; the Biographical Sketch Common Form is the specific, standardised template — shared across federal agencies under NSPM-33 alignment — that has been mandatory since 25 January 2026 and must be produced through SciENcv rather than a manually edited file.

    Transition deadlines and what research offices must verify

    The effective date is fixed: NIH Guide Notice NOT-OD-26-018 requires the Biographical Sketch Common Form and the Supplement for application due dates, and for Just-in-Time, Research Performance Progress Report, and Prior Approval submissions, on or after 25 January 2026. Confirm exactly which Common Forms a given opportunity requires against its Notice of Funding Opportunity, since transition scenarios vary by submission type.

    For research administration teams, that shifts the compliance-verification workload in three concrete ways:

    • Identity infrastructure, not just document review. Compliance now depends on whether every named person’s ORCID iD is correctly linked to eRA Commons and SciENcv — a check that must happen weeks before a deadline, not the night before submission.
    • Certification status over formatting checks. Since SciENcv locks formatting automatically, the meaningful pre-submission check is whether the PDF carries SciENcv’s digital certification, not whether margins and fonts look right.
    • Contribution narrative discipline. With citations stripped from the Personal Statement and Contributions to Science tied to a capped Products list, PIs need a clear way to describe prior contributions. Structured contributor-role taxonomies help here: CASRAI originated the CRediT contributor role taxonomy in 2014, now stewarded by NISO as ANSI/NISO Z39.104-2022. NIH does not require CRediT tags in a biosketch, but mapping a contribution against a defined CRediT role before drafting keeps “Contributions to Science” statements precise and defensible under review.

    Looking ahead: what PIs and institutions should do now

    The shift to SciENcv-generated biosketches is now in force, not pending — any PI or research office still working from a saved Word template is out of compliance. The priority list is short: confirm every senior/key person has an ORCID iD linked to eRA Commons, rebuild biosketches in SciENcv ahead of the next deadline, and update proposal-review checklists to look for SciENcv certification marks rather than page counts.

    Institutions that treat this as an identity-and-process change, not a one-off template swap, will avoid the scramble that follows when a funder mandate moves from “recommended” to “required” without warning. As other federal funders align their own forms to the same Common Form standard under NSPM-33, the SciENcv workflow described here is likely to become the baseline expectation well beyond NIH applications.

  • NIH RePORTER Explained: How to Search, Track, and Analyse Federal Grant Awards

    NIH RePORTER (Research Portfolio Online Reporting Tools Expenditures and Results) is the free public database and API through which the U.S. National Institutes of Health discloses its funded research portfolio. For research administrators running portfolio analysis, competitor intelligence, or funding prospecting, it is the single most important primary source for federal biomedical grant data — and one that is routinely underused because its filter logic and API are not self-explanatory.

    This guide is a practical walkthrough, not a policy explainer: how to search by principal investigator, how to build precise advanced-search queries, and how to pull structured award data programmatically via the API.

    What Is NIH RePORTER?

    NIH RePORTER (reporter.nih.gov) replaced the legacy RePORT system as NIH’s primary award-transparency tool. It indexes project records — abstracts, budgets, principal investigators, awarding institute, and public health relevance statements — alongside the publications, patents, and clinical trials those awards produced.

    The database is broader than its name suggests. Alongside NIH’s 27 Institutes and Centers, RePORTER also carries award data for several other Public Health Service funders, including the Centers for Disease Control and Prevention (CDC), the Agency for Healthcare Research and Quality (AHRQ), the Health Resources and Services Administration (HRSA), the Administration for Children and Families (ACF), and the Department of Veterans Affairs (VA). That makes it a de facto federal biomedical-funding index, not just an NIH tool.

    A companion service, ExPORTER, provides scheduled bulk downloads (CSV and flat-file formats) of the same underlying data for users who need to build local datasets rather than query interactively.

    RePORTER offers three distinct entry points, and choosing the right one saves significant time.

    Tool Best for Key inputs
    Quick Search Fast lookups when you already know a name, term, or project number Free text, PI name, project number, fiscal year
    Advanced Search Structured portfolio queries with multiple constraints Boolean text fields, activity code, IC, mechanism, org, geography
    Matchmaker Finding comparable funded projects from an abstract or specific aims Pasted abstract text; returns similar projects, study sections, program officials

    Advanced Search filters worth knowing

    The Advanced Search form supports Boolean operators (AND, OR, NOT) across several filter groups. The ones administrators use most often for portfolio and competitor analysis are:

    • Fiscal Year — single year or a range, for trend analysis across award cycles
    • Agency / Institute or Center (IC) — narrows to a specific NIH IC (e.g. NCI, NIAID) or non-NIH PHS agency
    • Activity Code — the grant mechanism (R01, U01, K award series, SBIR/STTR, etc.)
    • Organisation — recipient institution, useful for benchmarking a peer institution’s award volume
    • Project Terms — keyword search across abstracts and specific aims
    • Congressional District / Geography — for regional funding analysis

    Search results can be filtered further on the results page without re-running the query, and exported directly to CSV or Excel — the fastest route to a working dataset for a spreadsheet-based portfolio review.

    Using the NIH RePORTER API for Programmatic Analysis

    For recurring or large-scale queries — competitor tracking, institutional benchmarking, funding-landscape dashboards — the web interface does not scale. The NIH RePORTER API (api.reporter.nih.gov) is a RESTful JSON service built for exactly this use case.

    The API accepts POST requests with a JSON criteria object and mirrors the Advanced Search filter logic (fiscal year, IC, activity code, PI name, organisation, project terms) across four core endpoints: project search, publications, patents, and clinical studies. Requests do not require an API key, which lowers the barrier for institutional research-office teams building lightweight internal tools without a procurement cycle. Python and R wrapper libraries maintained by the open-source community simplify pagination and bulk pulls for analysts who prefer not to hand-build JSON payloads.

    A typical portfolio-analysis workflow combines the API with ExPORTER bulk files: use the API for targeted, current-cycle queries (this year’s awards to a named PI or institute) and ExPORTER for historical trend datasets spanning multiple fiscal years.

    Common Questions About NIH RePORTER

    Are NIH grant scores public?

    No. Peer-review summary statements and percentile scores are released only to the applicant via eRA Commons and are treated as confidential under the NIH Grants Policy Statement. NIH RePORTER instead publishes the funded outcome — abstract, budget, project period, and awarding institute — once an award is made.

    How do I find who funded a study?

    Search RePORTER by the project number quoted in a paper’s acknowledgements, or match the PI name and publication title under the “Linked Publications” data. The resulting project record shows the awarding NIH Institute or Center, funding mechanism, and total award amount.

    Who gets the most NIH funding?

    Large academic medical centres and research-intensive universities consistently rank highest by total award value. RePORTER’s organisation-level search and the “Awards by Location” tool let administrators rank recipient institutions for any fiscal year rather than relying on third-party league tables.

    Why This Matters for Research Administrators

    For portfolio analysis, RePORTER turns what used to be manual FOIA-style requests into a self-service query. Research development offices can benchmark a department’s award mix against peer institutions by activity code, or track a specific IC’s funding priorities over a rolling five-year window using the Fiscal Year filter.

    For competitor intelligence, the Matchmaker tool is the most underused feature: pasting a draft specific-aims page returns not just similar funded projects but the study sections and program officials most likely to review a related application — genuinely actionable pre-submission intelligence that most institutions still source informally through personal networks.

    For funding prospecting, combining Advanced Search filters (IC + activity code + project terms) with a saved, re-runnable API query lets a research office flag newly funded awards in an adjacent field within days of public posting, rather than waiting for a funder’s own announcement cycle.

    Looking Ahead

    NIH RePORTER’s underlying data architecture — structured award records, linked outputs, and an open API — is increasingly the template other funders are measured against. As UK and EU funders expand open-data commitments under initiatives aligned with cOAlition S and UKRI’s own transparency agenda, research offices that already have RePORTER-based workflows are better placed to extend the same portfolio-analysis discipline to non-US funders as comparable APIs mature.

    The practical takeaway for research administration teams is to treat RePORTER not as an occasional lookup tool but as a standing data source: a saved Advanced Search for competitor tracking, an API pull scheduled alongside grant-cycle reporting, and Matchmaker built into pre-submission workflows.

  • UK Research Integrity Office vs US ORI: Comparing Oversight Models

    For institutions with staff, students, or funding on both sides of the Atlantic, understanding how research misconduct is handled is not an academic curiosity — it shapes compliance obligations, reporting duties, and reputational risk. The UK Research Integrity Office (UKRIO) and the US Office of Research Integrity (ORI) are the two most frequently cited reference points for research integrity oversight in the English-speaking research world, yet they sit at opposite ends of the regulatory spectrum: one advisory, one statutory. This analysis sets out what separates the UK’s Concordat-based, self-governing model from the US’s federally regulated assurance regime, and what that gap means in practice for institutions and publishers operating across both jurisdictions.

    Overview: two philosophies of oversight

    The UK has no statutory research-integrity regulator. Instead, oversight is distributed across independent charities, a voluntary sector-wide concordat, and each institution’s own governance. The US, by contrast, ties oversight of biomedical and behavioural research directly to federal funding: any institution receiving Public Health Service (PHS) money — chiefly through the National Institutes of Health (NIH) — must operate under enforceable federal regulation.

    This is the single most important distinction for anyone comparing the two systems: the UK model relies on reputational and contractual incentives to drive good practice, while the US model relies on funding-conditional legal compliance.

    The UK model: UKRIO, the Concordat, and self-governance

    UKRIO was established in 2006 as an independent charity. It offers confidential, impartial advice to researchers, institutions, and members of the public on good research conduct and on handling allegations of misconduct — but it does not investigate cases itself. That responsibility sits with the research organisation where the alleged conduct occurred, guided by UKRIO’s Code of Practice for Research.

    Sitting alongside UKRIO is the Concordat to Support Research Integrity, first published by Universities UK in 2012 and substantially revised in 2019. The Concordat is a voluntary framework, not legislation, built around five commitments:

    • Maintaining the highest standards of rigour and integrity in research
    • Conducting research in an appropriate, ethically sound, and legally compliant way
    • Supporting a research environment that is underpinned by a culture of integrity
    • Using robust and fair processes to investigate allegations of misconduct
    • Working openly and transparently, including public reporting on research integrity

    UK Research and Innovation (UKRI) and Research England are among the Concordat’s signatories, alongside the UK’s major research funders and universities. More recently, UKRI has moved to strengthen system-level coordination through a Committee on Research Integrity, intended to work alongside UKRIO on cross-sector oversight rather than to replace institutional responsibility — a signal that the advisory model is being reinforced rather than converted into a regulator.

    One point that is often glossed over: UKRIO’s Code of Practice defines misconduct more broadly than the classic fabrication-falsification-plagiarism (FFP) triad. It also covers matters such as proceeding without necessary ethical approval, misrepresenting data or authorship, and breaching a researcher’s duty of care — a wider net than the narrower legal definition used in the US.

    The US model: ORI and federal regulatory assurance

    The Office of Research Integrity sits within the US Department of Health and Human Services (HHS), under the Office of the Assistant Secretary for Health. Its jurisdiction is defined by federal regulation — 42 CFR Part 93 — and applies to institutions receiving PHS funding, which includes the large majority of federally funded biomedical and behavioural research in the United States.

    Unlike UKRIO, ORI operates within an assurance framework: institutions receiving PHS funds must file an institutional assurance confirming they have policies and procedures for handling misconduct allegations that meet federal standards. Institutions still conduct the initial investigation, but ORI reviews and can reopen or challenge that process. Where misconduct is confirmed, ORI can recommend administrative actions to HHS, ranging from supervision and certification requirements to debarment from federal funding — a consequence with no direct UK equivalent, since UKRIO has no power to withhold funding from anyone.

    Critically, the federal definition of research misconduct that ORI enforces is narrower than UKRIO’s: fabrication, falsification, and plagiarism (FFP) only, as set out in 42 CFR §93.103. Authorship disputes, data-management failures, or ethics-approval breaches that UKRIO would treat as misconduct concerns typically fall outside ORI’s formal jurisdiction, though they may still be handled under an institution’s own policies.

    Comparing the two models side by side

    Feature UK: UKRIO / Concordat US: Office of Research Integrity
    Legal status Independent charity; voluntary sector concordat Federal agency within HHS
    Established 2006 (UKRIO); 2012, revised 2019 (Concordat) 1992
    Governing basis No statute; reputational/contractual adoption Federal regulation, 42 CFR Part 93
    Investigatory role Advisory only; institutions investigate Reviews/oversees institutional investigations
    Misconduct definition Broader — includes ethics-approval and duty-of-care breaches Narrower — fabrication, falsification, plagiarism only
    Enforcement power None; promotes good practice via guidance Can recommend sanctions, including funding debarment
    Scope All disciplines, all UK research organisations PHS-funded biomedical/behavioural research
    Funding model Subscribing institutions pay for UKRIO’s services Federally funded as part of HHS budget

    Common questions on research integrity oversight

    What is the UK Research Integrity Office?

    The UK Research Integrity Office (UKRIO) is an independent charity, established in 2006, that provides expert advice and guidance on good research practice and the handling of misconduct allegations. It has no statutory or investigatory powers — responsibility for investigating allegations remains with individual research institutions.

    What does the US Office of Research Integrity do?

    The Office of Research Integrity (ORI) is a federal agency within the US Department of Health and Human Services. It oversees research-misconduct policy for Public Health Service-funded research, reviews institutional investigations, and can recommend administrative sanctions, including funding debarment.

    What counts as research misconduct under UKRIO’s Code of Practice?

    UKRIO’s Code of Practice for Research defines misconduct more broadly than fabrication, falsification and plagiarism alone, also covering breaches such as proceeding without ethical approval, misrepresenting data, and failing in a researcher’s duty of care — a wider net than the US federal definition.

    What are the core commitments of the Concordat to Support Research Integrity?

    The Concordat to Support Research Integrity, revised in 2019, sets out five commitments covering rigour and transparency, appropriate governance, a supportive research environment, robust misconduct investigation, and transparent public reporting — voluntarily adopted by UK universities and funders including UKRI.

    Implications for multinational institutions and publishers

    For institutions operating research programmes, joint ventures, or staff exchanges across the UK and US, the practical consequence of these two models is a compliance asymmetry. A collaboration that falls short of UKRIO’s broader Code-of-Practice standard may still be technically compliant with ORI’s narrower FFP definition, and vice versa — an ethics-approval lapse that UKRIO would flag as a misconduct concern may sit outside ORI’s formal jurisdiction entirely.

    • Research administrators managing joint UK-US grants should map both frameworks into a single institutional misconduct policy rather than defaulting to whichever funder’s rules are stricter on paper.
    • Publishers and journal editors handling cross-border authorship disputes should recognise that a “no finding” outcome from a US institution under ORI’s FFP standard does not necessarily mean the same conduct would clear UKRIO’s Code of Practice, or vice versa.
    • Funders operating in both jurisdictions benefit from Concordat-style transparent reporting commitments even where they are not legally required, since it narrows the gap with ORI’s assurance-based accountability.

    Outlook: converging pressures, diverging structures

    Neither system shows signs of formally converging. The UK’s 2019 Concordat revision and UKRI’s growing coordination role reinforce, rather than replace, the advisory model; the US assurance regime remains anchored in federal regulation that would require congressional or HHS rule-making to change materially. What is converging is expectation: international publishers, funders such as Horizon Europe, and bodies like COPE and the Committee on Publication Ethics increasingly expect institutions to demonstrate research-integrity governance regardless of which national model applies. For multinational institutions, the practical answer is not to wait for the UK and US to align, but to build internal policy that satisfies the stricter of the two standards on every point where they diverge.